Navigation Links
ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
Date:9/28/2008

scular blockages, 33% of patients treated with microplasmin achieved reperfusion compared with 14% of placebo-treated patients. Due to the small number of patients in this study, neither of these end points were statistically significant. However, the study also showed that microplasmin-treated patients had a statistically significant improvement in the level of damage to the blood brain barrier compared to placebo-treated patients, measured using the marker of matrix metalloproteinase (MMP). MMP activation plays a crucial role in the pathogenesis of brain edema and hemorrhagic transformation after ischemic stroke.

Professor Vincent Thijs, Lead Principal Investigator of the trial, commenting on the results said, "I am delighted that we were able to present these interesting results at the World Stroke Congress. The results show that microplasmin is safe and generally well tolerated with no evidence of increased bleeding risk. Moreover, the results also support previous preclinical studies that have shown that microplasmin is able to lyse clots and may also have certain vascular protective properties."

Dr. Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement said: "I am very pleased that we have been able to successfully conclude this study of microplasmin in patients with stroke. The results that have been reported show that the product is well tolerated and could potentially be of benefit in this indication of high medical need. However, as we have stated previously, our current view is that it only makes sense for ThromboGenics to move forward with the development of microplasmin for vascular indications in cooperation with a partner, given the costs and risks involved. We believe that by focusing on the development of microplasmin for eye disease, where we have already generated encouraging clinical data, and carefully utilizing our resources on the other opportunities in our pipeline, we will continue to generate a high return f
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
3. Clinton Global Initiative Announces BDs Commitment to Biamba Marie Mutombo Hospital
4. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
5. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
8. Phosphagenics Announces Initiation of Phase 1 Clinical Trial in Humans for Its Transdermal Lidocaine
9. Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
10. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Today the U.S. Food and ... for the prevention of serogroup B meningococcal disease ... Pfizer,s vaccine Trumenba®, which received FDA approval in October, ... devastating disease. "I have heard over ...
(Date:1/23/2015)... lot of discussion in the medical community revolves around figuring ... conditions. As medical science advances, doctors and surgeons often feel ... consider to be more cutting edge. Yet, when it comes ... treatment that stands out as the best solution in all ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) ... health care leaders and a new study analyzing the impact of ... is a nationwide coalition working to educate policy makers and the ... the Capitol was focused on how the Iowa ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3
... , CLEVELAND, Nov. 30 DATATRAK International, Inc. (OTCQX: ... solutions for the clinical trials industry, today announced that PFC ... PFC will now have the ability to contract for DATATRAK,s ... product suite. In addition, PFC will also have access ...
... Breast-Specific Gamma Imaging (BSGI) has been proven to be ... carcinoma in situ (DCIS), a difficult to diagnose breast cancer. ... lesions independent of tissue density and discover very early stage ... of the Radiological Society of North America (RSNA), BSGI is ...
Cached Medicine Technology:PFC Pharma Joins DATATRAK's CRO Connect Program 2PFC Pharma Joins DATATRAK's CRO Connect Program 3PFC Pharma Joins DATATRAK's CRO Connect Program 4Breast-Specific Gamma Imaging Proves Highly Sensitive for the Detection of Ductal Carcinoma In Situ 2
(Date:1/23/2015)... Phoenix, AZ (PRWEB) January 23, 2015 Hastings ... personal injury matters, reports a record number of legal representation ... Statistically speaking, there has been a steady rise in the ... at work and at home throughout the Valley. With that ... their accident be reviewed by an experienced law firm. Hastings ...
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has ... the business is showing its latest designs of wedding dresses ... to the company’s CEO, all the fresh new products are ... discounts, up to 80% off. All the clothes from LunaDress ...
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... Square are quitting the NHS on April 1. Dentists in ... health contracts by April 1st. // Several Cumbrian practices have ... three months notice when leaving the NHS. ,But ... just a few days notice. The North Cumbria Primary Care ...
... be examined for effectiveness in the fight against bird flu ... Organization., // ,WHO, in a statement from Geneva, said ... the deadly H5N1 virus is there. Therefore urgent studies need ... Tamiflu should be used to treat suspected cases and to ...
... not good news but there is a silver lining. Those ... later onset to develop kidney failure in adulthood.// ... medical journal Diabetes Care. ,Dr. Maria Svensson, of Umea ... data from two nationwide registers, which include 12,032 cases of ...
... University’s Lombardi Comprehensive Cancer Center have managed to separate ... functions like bone development. //It is generally accepted that ... dosage intended to take advantage of its anticancer properties ... that we might be able to separate the two ...
... women who have cancer in one breast and decide to ... good quality of life despite popular perception to the contrary. ... decisions to have the preventive mastectomy in addition to their ... from Wake Forest University School of Medicine. “And women who ...
... which reports about the HIV infection in Victoria said that ... ,Greg Iverson, president of People Living with HIV-AIDS Victoria said ... are rethinking about their policies after infection rates soared. The ... 45 years old. , Brent Allan, who runs ...
Cached Medicine News:Health News:HIV Infection Rates on the Rise in Victoria 2
... Gel Bed dimensions: 7.5cm(w) x 10cm(l). ... casting in the unit. Gel bed ... blue, yellow, pink, purple, or green. ... and dual sided combs, and Flip-Lid versions ...
... Submerged horizontal gels offer many advantages ... a primary tool for the molecular biologist. ... readily dissipate heat. These gels allow sample ... by wicks or sample well dehydration. Horizontal ...
... with 7 x 10 cm tray and ... gel electrophoresis of nucleic acids in mini ... The system includes an electrophoresis cell, 7 ... gates, mini-gel caster, and two 1.5 mm ...
... cell GT system, with 7 x ... submerged horizontal gel electrophoresis of nucleic ... 10 cm agarose gels. The system ... 10 cm UV-transparent gel tray, casting ...
Medicine Products: